Table 2 Molecular characteristics of anti-CGRP monoclonal antibodies and gepants. Adapted from [64, 69,70,71]
From: Mode and site of action of therapies targeting CGRP signaling
| Â | Gepants | Anti-CGRP monoclonal antibodies |
|---|---|---|
Target | CGRP receptor | CGRP receptor or ligand |
Clearance | Liver, kidney | Reticuloendothelial system |
Half-life | 5–11 h | 3–7 weeks |
Size | 0.5–0.6 kDa | 143–146 kDa |
Ability to cross blood–brain barrier | Low (1.4% CSF/plasma ratio) | No |
Administration | Oral, intranasal | Parenteral |
Immunogenicity | No | Yes |